氯胺酮
医学
耐火材料(行星科学)
加药
麻醉
类阿片
现存分类群
病因学
缓和医疗
重症监护医学
精神科
药理学
内科学
物理
护理部
受体
天体生物学
生物
进化生物学
作者
Christopher Kerr,Timothy Holahan,Robert Austin Milch
标识
DOI:10.1089/jpm.2010.0424
摘要
The benefits of ketamine in reducing pain are largely based on case reports and small clinical trials. We present a case series describing the application and efficacy of subanesthetic doses of ketamine in the treatment of complex pain syndromes poorly responsive to escalating doses of opioids. The discussion that follows suggests that subanesthetic intravenous ketamine can be used to successfully treat severe pain of different etiologies refractory to opioid dose escalation. Optimal dosing titration, duration of initial treatment, and the role of maintenance ketamine need to be further elucidated. Our case series adds to the extant literature supporting the role of subanesthetic ketamine for refractory pain problems.
科研通智能强力驱动
Strongly Powered by AbleSci AI